CCIA
IMMU

Campbell & Co Investment Adviser’s Immunomedics Inc IMMU Stock Holding History

Campbell & Co Investment Adviser’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,887
Closed -$209K – 514
2020
Q2 		$209K Buy
+5,887
New +$172K 0.26% 208

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Campbell & Co Investment Adviser's IMMU Position: Q3 2020 in Review

Campbell & Co Investment Adviser sold out of Immunomedics Inc (IMMU) in Q3 2020, closing a stake of 5,887 shares — an estimated $209K sold.

Campbell & Co Investment Adviser first reported a position in IMMU in Q2 2020 and held it in 1 quarter. The position peaked at $209K in Q2 2020. 408 funds tracked by Wall St. Rank hold IMMU as of Q3 2020.

  • Campbell & Co Investment Adviser reported no remaining Immunomedics Inc position as of Q3 2020 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 5,887 Immunomedics Inc shares in Q3 2020, an estimated $209K.
  • Campbell & Co Investment Adviser first reported a position in Immunomedics Inc in Q2 2020 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Immunomedics Inc position peaked at $209K in Q2 2020.
  • 408 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2020.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2020, filed 15 Oct 2020.